Idorsia Ltd

IDIA

Equity

ISIN CH0363463438 / Valor 36346343

SIX Swiss Exchange (2026-04-29)

CHF 3.64+4.78%

Idorsia Ltd
UMushroom community rating:

3.89 25 votes No rating yet

NegativeNeutralPositive

About company

Idorsia Ltd is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. The company aims to address significant unmet medical needs by advancing a diverse pipeline of drug candidates across various therapeutic areas. Idorsia's research and development efforts are concentrated on creating novel treatments that can improve patient outcomes. With a commitment to scientific excellence, the company leverages its expertise in drug discovery and development to bring new therapies to market. Headquartered in Switzerland, Idorsia operates with a global perspective, seeking to make a meaningful impact on healthcare through its innovative pharmaceutical solutions.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

230%1Y

-54.1%3Y

-83.6%5Y

Performance

75.0%1Y

101%3Y

82.5%5Y

Volatility

1163 M

Market cap (USD)

4,667,427

Daily traded volume (Shares)

0.849 / 0.78

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

3.89

25 votes

Performance:

3.47

Innovation:

3.99

Society:

3.82

Nature:

3.54

Viktor Stockel

Switzerland, 22 Mar 2026

Overall a good company

Shana Locher

Switzerland, 22 Mar 2026

Idorsia is a high-risk biotech turnaround with strong innovation potential. Revenue is growing, but profitability remains negative and financing risks persist. Success depends heavily on pipeline execution and commercialization of key drugs.

Nicolas Allet

Switzerland, 21 Mar 2026

Innovative biotech with strong R&D pipeline, but weak financial performance and high cash burn. Success depends heavily on drug approvals and commercialization execution.

EQUITIES OF THE SAME SECTOR

Progyny Inc